Viatris price to book ratio VTRS
Market value divided by the book value of the company's net assets, since 2021.
- Today, Oct 23, 2026
- 1.4×
- 6-year median
- 0.7×
- Against its 6-year history
- 99th
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 0.5× to 1.5×
- Peer median
- 3.6×
Viatris' price to book ratio is 1.4× as of Oct 23, 2026.
That is above its 6-year median of 0.7×, higher than on 99% of days in the last 6 years.
Over that time it ranged from 0.5× in Apr 2025 to 1.5× in Oct 2026.
The median for 10 healthcare stocks of a similar size is 3.6×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.4× | 0.9× | 1.5× |
| 2025 | 0.9× | 0.5× | 0.9× |
| 2024 | 0.8× | 0.6× | 0.8× |
| 2023 | 0.6× | 0.5× | 0.8× |
| 2022 | 0.7× | 0.5× | 0.9× |
| 2021 | 0.8× | 0.7× | 0.9× |
Against its peers
Companies in Healthcare nearest Viatris' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| VTRSViatris | 1.4× |
| THCTenet Healthcare | 4.6× |
| STESTERIS | 3.1× |
| ZBHZimmer Biomet | 1.5× |
| MEDPMedpace | 43.1× |
| INCYIncyte | 3.7× |
| RVTYRevvity | 2.5× |
| UTHRUnited Therapeutics | 3.9× |
| LHLabcorp | 3.1× |
| DGXQuest Diagnostics | 3.6× |
| EXELExelixis | 8.7× |
| Peer median | 3.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Viatris
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.